Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Sutro Biopharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.77 |
52 Week High | US$6.13 |
52 Week Low | US$2.01 |
Beta | 1.22 |
11 Month Change | 16.56% |
3 Month Change | 1.21% |
1 Year Change | -15.39% |
33 Year Change | -77.96% |
5 Year Change | -66.89% |
Change since IPO | -75.23% |
Recent News & Updates
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%
Jun 26We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right
May 31Recent updates
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%
Jun 26We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right
May 31Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Aug 11Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M
Aug 08Sutro to get $10M payment from Merck after first patient dosed in collaboration trial
Jul 26Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Dec 27Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates
Jun 18Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts
May 09Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
May 07Sutro Biopharma EPS misses by $0.04, beats on revenue
May 07Shareholder Returns
STRO | US Biotechs | US Market | |
---|---|---|---|
7D | -10.8% | 0.2% | -2.1% |
1Y | -15.4% | 12.5% | 19.0% |
Return vs Industry: STRO underperformed the US Biotechs industry which returned 12.5% over the past year.
Return vs Market: STRO underperformed the US Market which returned 19% over the past year.
Price Volatility
STRO volatility | |
---|---|
STRO Average Weekly Movement | 11.6% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: STRO has not had significant price volatility in the past 3 months.
Volatility Over Time: STRO's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 300 | Bill Newell | www.sutrobio.com |
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Sutro Biopharma, Inc. Fundamentals Summary
STRO fundamental statistics | |
---|---|
Market cap | US$307.96m |
Earnings (TTM) | -US$114.96m |
Revenue (TTM) | US$154.07m |
2.0x
P/S Ratio-2.7x
P/E RatioIs STRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
STRO income statement (TTM) | |
---|---|
Revenue | US$154.07m |
Cost of Revenue | US$197.90m |
Gross Profit | -US$43.84m |
Other Expenses | US$71.12m |
Earnings | -US$114.96m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.41 |
Gross Margin | -28.45% |
Net Profit Margin | -74.62% |
Debt/Equity Ratio | 0% |
How did STRO perform over the long term?
See historical performance and comparison